Literature DB >> 29185148

Therapeutic prospects of microRNAs in cancer treatment through nanotechnology.

Rajendra Awasthi1, Michael John Rathbone2,3, Philip Michael Hansbro4, Mary Bebawy5, Kamal Dua6,7.   

Abstract

MicroRNAs (miRNAs) represent a new class of diagnostic and prognostic biomarker as well as new therapeutic targets in cancer therapy. miRNAs are gaining significant interest due to extensive advancements in knowledge since their discovery and, more recently, their translational application as therapeutic moieties and targets in the management of disease. miRNAs used in the treatment of cancer would position them as a new class of emerging therapeutic agents. Indeed, numerous candidate miRNAs have been identified as having therapeutic application in the treatment of cancer, but there is still much to learn about how to transform these into effective, patient-compliant, and targeted drug delivery systems. In this mini review, we discuss the utility and potential of nanotechnology in miRNA formulation and delivery with particular emphasis on cancer, including their role in conferring multidrug resistance and metastatic capacity. This review benefits both the formulation and biological scientists in understanding and exploring the new vistas of miRNA delivery using nanotechnology in the cancer clinically.

Entities:  

Keywords:  Cancer; Extracellular vesicles; Metastasis; MicroRNA; Microparticles; Multidrug resistance; Nanotechnology; P-Glycoprotein

Mesh:

Substances:

Year:  2018        PMID: 29185148     DOI: 10.1007/s13346-017-0440-1

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  121 in total

Review 1.  MicroRNAs: small RNAs with a big role in gene regulation.

Authors:  Lin He; Gregory J Hannon
Journal:  Nat Rev Genet       Date:  2004-07       Impact factor: 53.242

Review 2.  Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.

Authors:  Edgar Pérez-Herrero; Alberto Fernández-Medarde
Journal:  Eur J Pharm Biopharm       Date:  2015-03-23       Impact factor: 5.571

Review 3.  microRNA and cancer.

Authors:  Mengfeng Li; Jun Li; Xiaofan Ding; Mian He; Shi-Yuan Cheng
Journal:  AAPS J       Date:  2010-04-28       Impact factor: 4.009

4.  Pre-clinical results with Clariscan (NC100150 Injection); experience from different disease models.

Authors:  A Bjørnerud; L O Johansson; H K Ahlström
Journal:  MAGMA       Date:  2001-05       Impact factor: 2.310

Review 5.  Cancer biomarker detection: recent achievements and challenges.

Authors:  Li Wu; Xiaogang Qu
Journal:  Chem Soc Rev       Date:  2015-03-05       Impact factor: 54.564

Review 6.  Challenges and strategies in anti-cancer nanomedicine development: An industry perspective.

Authors:  Jennifer I Hare; Twan Lammers; Marianne B Ashford; Sanyogitta Puri; Gert Storm; Simon T Barry
Journal:  Adv Drug Deliv Rev       Date:  2016-04-29       Impact factor: 15.470

7.  Deciphering Cell-to-Cell Communication in Acquisition of Cancer Traits: Extracellular Membrane Vesicles Are Regulators of Tissue Biomechanics.

Authors:  Deep Pokharel; Philip Wijesinghe; Vici Oenarto; Jamie F Lu; David D Sampson; Brendan F Kennedy; Vincent P Wallace; Mary Bebawy
Journal:  OMICS       Date:  2016-08

8.  A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells.

Authors:  Rajib Ghosh; Lalithya C Singh; Jason M Shohet; Preethi H Gunaratne
Journal:  Biomaterials       Date:  2012-10-27       Impact factor: 12.479

9.  Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles.

Authors:  Amanda Tivnan; Wayne Shannon Orr; Vladimir Gubala; Robert Nooney; David E Williams; Colette McDonagh; Suzanne Prenter; Harry Harvey; Raquel Domingo-Fernández; Isabella M Bray; Olga Piskareva; Catherine Y Ng; Holger N Lode; Andrew M Davidoff; Raymond L Stallings
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

10.  The Business of RNAi Therapeutics in 2012.

Authors:  Dirk Haussecker
Journal:  Mol Ther Nucleic Acids       Date:  2012-02-07       Impact factor: 10.183

View more
  10 in total

Review 1.  Delivery of therapeutic miRNA using polymer-based formulation.

Authors:  Eunmi Ban; Taek-Hyun Kwon; Aeri Kim
Journal:  Drug Deliv Transl Res       Date:  2019-12       Impact factor: 4.617

Review 2.  Improved understanding of gastrointestinal stromal tumors biology as a step for developing new diagnostic and therapeutic schemes.

Authors:  Marta Magdalena Fudalej; Anna Maria Badowska-Kozakiewicz
Journal:  Oncol Lett       Date:  2021-03-28       Impact factor: 2.967

3.  miRNA nanotherapeutics: potential and challenges in respiratory disorders.

Authors:  Meenu Mehta; Dinesh K Chellappan; Peter R Wich; Nicole G Hansbro; Philip M Hansbro; Kamal Dua
Journal:  Future Med Chem       Date:  2020-04-09       Impact factor: 3.808

4.  microRNA-877-5p exerts tumor-suppressive functions in prostate cancer through repressing transcription of forkhead box M1.

Authors:  Bin Yang; Huifeng Diao; Pu Wang; Fengju Guan; Hechen Liu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Inhibition of miR‑98‑5p promotes high glucose‑induced suppression of preosteoblast proliferation and differentiation via the activation of the PI3K/AKT/GSK3β signaling pathway by targeting BMP2.

Authors:  Feng Zheng; Fucai Zhang; Furong Wang
Journal:  Mol Med Rep       Date:  2022-07-29       Impact factor: 3.423

Review 6.  A Quality by Design Approach in Pharmaceutical Development of Non-Viral Vectors with a Focus on miRNA.

Authors:  Ioana Toma; Alina Silvia Porfire; Lucia Ruxandra Tefas; Ioana Berindan-Neagoe; Ioan Tomuță
Journal:  Pharmaceutics       Date:  2022-07-16       Impact factor: 6.525

Review 7.  The Multiple Roles of Hepatitis B Virus X Protein (HBx) Dysregulated MicroRNA in Hepatitis B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) and Immune Pathways.

Authors:  Kurt Sartorius; Leo Swadling; Ping An; Julia Makarova; Cheryl Winkler; Anil Chuturgoon; Anna Kramvis
Journal:  Viruses       Date:  2020-07-10       Impact factor: 5.818

8.  Downregulation of miR-205 contributes to epithelial-mesenchymal transition and invasion in triple-negative breast cancer by targeting HMGB1-RAGE signaling pathway.

Authors:  Ling Wang; Fu-Biao Kang; Juan Wang; Chao Yang; Dong-Wei He
Journal:  Anticancer Drugs       Date:  2019-03       Impact factor: 2.248

9.  Norepinephrine-CREB1-miR-373 axis promotes progression of colon cancer.

Authors:  Jia Han; Qiuyu Jiang; Ruili Ma; Huahua Zhang; Dongdong Tong; Kaijie Tang; Xiaofei Wang; Lei Ni; Jiyu Miao; Baojun Duan; Yang Yang; Yanke Chen; Fei Wu; Jiming Han; Mengchang Wang; Ni Hou; Chen Huang
Journal:  Mol Oncol       Date:  2020-03-13       Impact factor: 6.603

Review 10.  Nucleic Acid-Based Approaches for Tumor Therapy.

Authors:  Simone Hager; Frederic Julien Fittler; Ernst Wagner; Matthias Bros
Journal:  Cells       Date:  2020-09-09       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.